Skip to content

The effect of gasterojejunal anastomosis size on Excess Body Mass Index Loss (EBMIL) and Roux-en-Y bypass outcomes

The effect of 30 and 45 mm gasterojejunal anastomosis size with fixed 125 cm biliopancreatic limb and 75 cm alimentary limb on Excess Body Mass Index Loss (EBMIL) and Roux-en-Y bypass outcomes in the patients with morbid obesity; a double- blinded clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180507039572N1
Enrollment
70
Registered
2021-02-13
Start date
2021-03-05
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Morbid obesity. Diabetes mellitus due to underlying condition Morbid (severe) obesity due to excess calories

Interventions

Intervention 1: Intervention 1 "Receiving 45 mm gasterojejunal anastomosis": Patients in this group will be placed in French (Y-shaped) surgical position after general anesthesia so that the surgeon c

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Candidate for Roux-en Y surgery Satisfaction to participate in the study Age over 18 years Body mass index more or equal to 40 and less or equal to 50

Exclusion criteria

Exclusion criteria: History of major gastrointestinal surgery Having general conditions that prevent surgery under general anesthesia Age over 75 years Having Crohn's inflammatory disease Family history of gastric cancer Severe intestinal adhesions

Design outcomes

Primary

MeasureTime frame
Excess Body Mass Index Loss (EBMIL). Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Using the following formula obtained from the body mass index: (Pre-operative BMI – Current BMI) / (Pre-operative BMI – 25) × 100.

Secondary

MeasureTime frame
Diabetes remission. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Using Buchwald criteria (FPG <100 mg/dl or A1C <6 %).;Insulin. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Fasting blood sugar. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Glocuse, 2 hour Post Prandial. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;C-Peptide. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;HbA1C. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Lipid profile. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Systolic blood presser. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Barometer.;Diastolic blood pressure. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Barometer.;Dumping. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Physical examination.;Hemoglobin. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Liver porfile. Timepoint: Before the intervention, one, three and six months after the intervention. Method of measurement: Blood sampling.;Quality of life. Timepoint: Six months after the intervention. Method of measurement: BAROS quality of life consisting of 5 items (self-esteem, work conditions, physical activity, social activity and sexual Activity). Each item consists of 5 options (much better, be

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRohollah Valizadeh

Iran University of Medical Sciences

rohvali4@gmail.com+98 21 8670 5512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026